Beverly Wilshire reported FY 2025 revenue of SGD 9.4 million (+60%) and gross profit of SGD 5.3 million (+72%), with gross margin at 56% (from 52%). The group posted net profit of SGD 67,000, compared with a prior-year net loss, while profit attributable to shareholders was SGD 46,000; basic and diluted EPS was 0.005 cents. Q4 revenue was SGD 2.4 million (+72%) and the group recorded a Q4 net loss of SGD 62,000. As at 31 December 2025, Beverly Wilshire had cash and bank balances of SGD 572,000 and total assets of SGD 5.7 million, with net assets of SGD 168,000 (NAV per share: 0.015 cents). The company said there was no revenue from its trading and distribution segment in FY 2025, and attributed the revenue increase mainly to higher contributions from its aesthetic medical and healthcare operations in Kuala Lumpur. It also cited higher marketing agency fees as a driver of FY 2025 distribution expenses of SGD 1.2 million, and noted a deposit of SGD 2.6 million as part payment for the proposed acquisition of the second floor of Tower A of Nobel Healthcare Park. No dividend was declared for FY 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beverly Wilshire Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: Z0WGN9XIEL7EO1UF) on February 27, 2026, and is solely responsible for the information contained therein.
Comments